SCHEMBL6035699

SCHEMBL6035699

CCOC(=O)c1cn(-c2ccc(C(F)(F)F)cn2)nc1C(C)CC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.55
MAPT P10636 3/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
HPGD P15428 1/20 0.48
KDM4E B2RXH2 4/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
POLB P06746 2/20 0.44
MLYCD O95822 1/20 0.43
LMNA P02545 2/20 0.42
TP53 P04637 1/20 0.42
GAA P10253 1/20 0.41
TIPARP Q7Z3E1 1/20 0.38
THRB P10828 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA2B P29275 1/20 0.37
ADORA1 P30542 1/20 0.37
GCGR P47871 1/20 0.37
FOS P01100 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6034641 0.92 SMN1; SMN2 (0.53) SMN1; SMN2MAPTNPC1RAB9AHPGD
SCHEMBL6034721 0.92 SMN1; SMN2 (0.57) SMN1; SMN2MAPTNPC1RAB9AHPGD
SCHEMBL6036413 0.91 SMN1; SMN2 (0.56) SMN1; SMN2MAPTNPC1RAB9AHPGD
SCHEMBL6035327 0.85 SMN1; SMN2 (0.61) SMN1; SMN2MAPTNPC1RAB9AHPGD
SCHEMBL20098715 0.83 SMN1; SMN2 (0.65) SMN1; SMN2MAPTNPC1RAB9AHPGD
SCHEMBL6034508 0.82 SMN1; SMN2 (0.45) SMN1; SMN2MAPTNPC1RAB9AHPGD
SCHEMBL6035696 0.81 SMN1; SMN2 (0.57) SMN1; SMN2MAPTNPC1RAB9AHPGD
SCHEMBL719337 0.80 PANK3 (0.42) SMN1; SMN2MAPTNPC1RAB9AHPGD
SCHEMBL6034687 0.80 SMN1; SMN2 (0.55) SMN1; SMN2MAPTNPC1RAB9AHPGD
SCHEMBL6036094 0.78 SMN1; SMN2 (0.41) SMN1; SMN2MAPTNPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 SMN1; SMN2 4408/4885MAPT 4741/4885NPC1 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.